Business
Roche Pays Up to $1.53B for Simcere’s Three-Armed Antibody Targeting Autoimmune Disease
The deal buys rights to an early-stage “tri-specific” antibody built to hit B cells — drivers of many autoimmune conditions — from multiple angles at once.